New cancer drug passes phase 1 trial?
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
%
▲ 00
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
6H
1D
1W
1M
ALL
Before 2026
$28,608vol
Order book
Rules summary
If a Phase II clinical trial has been announced for AOH1996 by December 31, 2025 (even if the trial has not started by that date), then the market resolves to Yes. Outcome verified from Clinicaltrials.gov.
Timeline and payout
About
AOH1996 is a novel cancer treatment drug that targets PCNA (proliferating cell nuclear antigen), a protein present in all dividing cells. Because AOH1996 inhibits PCNA, this type of drug is referred to as a PCNA inhibitor. Early tests suggest that AOH1996 may specifically target cancer cells while sparing normal cells. The drug is currently in Phase 1 clinical trials.
Show more
New cancer drug passes phase 1 trial?
Buy YesBuy
Sell
Dollars
Pick a side